An amendment to this paper has been published and can be accessed via a link at the top of the paper.
View Article and Find Full Text PDFObjectives: Biologics treatment with antitumour necrosis factor alpha (TNFα) is efficacious in patients with juvenile idiopathic arthritis (JIA). Despite displaying clinical inactivity during treatment, many patients will flare on cessation of therapy. The inability to definitively discriminate patients who will relapse or continue to remain in remission after therapy withdrawal is currently a major unmet medical need.
View Article and Find Full Text PDF